Lifeloc Q1 2022 net loss $145K vs profit $403K in Q1 2021, revenue up 19% to $2.161M

Lifeloc Technologies, Inc

2022-Q1 EPS reported -$0.06 revenue$2,160,636

Net loss of $145K ($0.06 diluted EPS) vs. net profit of $403K ($0.16 diluted EPS) in Q1 2021, which included a $465K PPP loan forgiveness gain.
Revenue $2.161M, up 19% YoY, driven by demand recovery and new product adoption.
R&D investment increased to develop SpinDx drug testing platform; expects initial SpinDx sales this year.
New LX9 and LT7 devices driving strong sales growth; L-series products gaining market traction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.